Clinical trial • Phase II • Cardiology

CDR132L for Heart failure

Phase II trial of CDR132L for Heart failure.

Overview

Trial Therapeutic Area
Cardiology
Trial Disease
Heart failure
Trial Stage
Phase II

Key dates

Initial CTIS Submission Date
20-10-2025
First CTIS Authorization Date
26-01-2026

Trial design

CDR132L administered subcutaneously compared to intravenous administration (route comparison); dose and schedule not specified in source.-controlled Phase II trial across 1 site in Germany.

Comparator
CDR132L administered subcutaneously compared to intravenous administration (route comparison); dose and schedule not specified in source.
Target Sample Size
32

Eligibility

Recruits 32 Vulnerable population selected (isVulnerablePopulationSelected = true); no further details on consent or assent handling provided in the source..

Vulnerable Population
Vulnerable population selected (isVulnerablePopulationSelected = true); no further details on consent or assent handling provided in the source.

Recruitment

Planned Sample Size
32
Recruitment Window Months
6

Geography

Total Number Of Sites
1
Total Number Of Participants
32

Germany

Earliest CTIS Part Ii Submission Date
10-12-2025
Latest Decision Or Authorization Date
26-01-2026
Processing Time Days
47
Number Of Sites
1
Number Of Participants
32

Sites

Site Name
Klinikum Westend Haus 31
Department Name
1: Parexel Early Phase Unit Berlin
Contact Person Name
Javier Hernandez
Number Of Participants
32

Sponsor

Primary sponsor

Full Name
Novo Nordisk A/S
Organisation Type
Pharmaceutical company
Country Of Registered Address
Denmark

Contract research organisations

Name
PAREXEL International GmbH
Responsibilities
Listed as trial site organisation and contact; present in trialSites with contact information.

Investigational products

Investigational Product Name
CDR132L
Routes Of Administration
Subcutaneous; Intravenous

Related trials

Other published trials that may interest you.